Ongoing Clinical Trials for Extraskeletal Myxoid Chondrosarcoma
There is currently 1 ongoing clinical trial for extraskeletal myxoid chondrosarcoma. This trial focuses on the long-term safety of tazemetostat, a medication that targets specific enzymes in cancer cells, for patients who have previously participated in tazemetostat studies and shown benefit from the treatment. The trial is being conducted in France and Poland.
Clinical trial locations
- France
- Poland
Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials
This study is designed to monitor the long-term safety of tazemetostat, a medication taken as a film-coated tablet by mouth. The trial is specifically for patients who have already received tazemetostat in previous clinical studies and have experienced clinical benefit from this treatment.
Who can participate?
To be eligible for this trial, you must:
- Be currently receiving or have previously received tazemetostat treatment with proven clinical benefit
- Have a life expectancy of more than 3 months
- Have adequate blood cell counts, bone marrow function, blood clotting factors, kidney function, and liver function
- Be willing and able to provide written informed consent and follow all study requirements
Additional requirements apply based on your ability to have children. Women who can become pregnant must have a negative pregnancy test at study entry and agree to use both a highly effective birth control method (such as implants, injections, birth control pills, or intrauterine devices) and a barrier method (such as condoms) during treatment and for 6 months afterwards. Men must have had a successful vasectomy and use condoms, or ensure their partner uses effective contraception throughout the study and for 3 months after stopping treatment.
Who cannot participate?
You will not be eligible for this study if you:
- Are not currently receiving tazemetostat treatment in a previous clinical study
- Have experienced severe side effects during previous treatment with tazemetostat
- Are unable to comply with the long-term safety monitoring requirements
- Have developed any medical condition that makes continued treatment unsafe
- Have withdrawn consent from your previous tazemetostat study
- Have missed scheduled doses or failed to follow study procedures in your previous trial
- Have developed progressive disease while on tazemetostat treatment
- Are participating in other clinical trials simultaneously
- Cannot continue long-term follow-up visits as required by the study protocol
What is the focus of this trial?
The main goal of this study is to evaluate how safe tazemetostat is when used over an extended period. Researchers will track any side effects that may occur and monitor how well patients tolerate the medication over time. The study will also measure various health parameters, including blood cell counts, kidney function, and liver function. Additionally, the study will track how long patients survive while receiving the treatment.
This is an open-label study, which means all participants will receive the active medication without the use of a placebo. The medication will be provided according to each patient’s previous treatment plan, either alone or in combination with other approved or experimental medications. The study is planned to continue until September 2025, and your participation duration will depend on your individual response to treatment and any side effects you may experience.
What medication is being tested?
Tazemetostat is the investigational drug in this trial. It belongs to a class of medications called EZH2 inhibitors, which work by blocking the EZH2 protein. This protein plays an important role in controlling gene expression and cancer cell growth. By blocking this protein, tazemetostat helps control the growth of certain types of cancer cells. The medication is taken orally as a film-coated tablet and represents an innovative approach in targeted cancer therapy.
Summary
Currently, there is one clinical trial available for patients with extraskeletal myxoid chondrosarcoma. This trial is accessible to patients in France and Poland and focuses exclusively on the long-term safety monitoring of tazemetostat. Importantly, this trial is only open to patients who have already participated in previous tazemetostat studies and have shown clinical benefit from the treatment.
The trial represents an important opportunity for patients who have responded well to tazemetostat to continue receiving the medication while contributing to the understanding of its long-term safety profile. The study requires strict adherence to monitoring schedules and contraception requirements, reflecting the careful approach needed when evaluating long-term medication safety.
